Gyre Therapeutics announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone), aimed at treating liver fibrosis caused by chronic hepatitis B (CHB). This acceptance follows the priority review status granted in March, highlighting the potential of F351 to address a significant medical need in China, where millions suffer from HBV infection leading to liver fibrosis and cirrhosis. Gyre plans further development in the U.S., including filing an Investigational New Drug application by the end of 2026 and initiating Phase 2 trials if approved. This milestone advances Gyre's efforts to commercialize innovative treatments for liver fibrosis globally.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
